<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05006794</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-467-5643</org_study_id>
    <nct_id>NCT05006794</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies</brief_title>
  <official_title>A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of Part A of this study is to define the maximum tolerated dose (MTD)&#xD;
      or maximum administered dose of GS-9716 as monotherapy in advanced solid malignancies and to&#xD;
      characterize the safety, and tolerability of GS-9716 monotherapy.&#xD;
&#xD;
      The primary objectives of Parts B and C of this study are: To characterize the safety,&#xD;
      tolerability, and to define MTD and/or recommended Phase 2 dose (RP2D) of GS-9716 in&#xD;
      combination with either docetaxel or sacituzumab govitecan-hziy in adults with metastatic&#xD;
      non-squamous non-small cell lung cancer (NSCLC) following treatment for metastatic disease,&#xD;
      including an immune checkpoint inhibitor and a single line of platinum containing&#xD;
      chemotherapy (for Cohorts B1, B2, C1, and C2) and in adults with metastatic triple-negative&#xD;
      breast cancer (TNBC) following a single line of therapy for metastatic disease (for Cohorts&#xD;
      B3, B4, C3, and C4); To characterize the safety, tolerability, and to define MTD and/or the&#xD;
      RP2D of GS-9716 in combination with gemcitabine and docetaxel in metastatic soft tissue&#xD;
      sarcomas (mSTS) with nonspecific histologies previously untreated for metastatic disease (for&#xD;
      Cohorts B5 and C5).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">May 2028</completion_date>
  <primary_completion_date type="Anticipated">March 2027</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>First dose date up to 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Adverse Events (AEs) According to National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE), Version 5.0</measure>
    <time_frame>First dose date up to last dose date (Maximum: 105 weeks) plus 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Laboratory Abnormalities According to NCI CTCAE, Version 5.0</measure>
    <time_frame>First dose date up to last dose date (Maximum: 105 weeks) plus 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for GS-9716</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) for GS-9716</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) for GS-9716</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Objective Response Rate (ORR)</measure>
    <time_frame>Up to 105 weeks</time_frame>
    <description>ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) as assessed by response evaluation criteria in solid tumors (RECIST) version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Confirmed ORR</measure>
    <time_frame>Up to 105 weeks</time_frame>
    <description>Confirmed ORR is defined as the percentage of participants who achieve a confirmed CR or confirmed PR by RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Disease Control Rate (DCR)</measure>
    <time_frame>Up to 105 weeks</time_frame>
    <description>DCR is defined as the percentage of participants who achieve a CR, PR, or stable disease (SD) as assessed by RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Progression-Free Survival (PFS)</measure>
    <time_frame>First dose date to PD or death, whichever occurs first (up to 39 months)</time_frame>
    <description>PFS is defined as the interval from the first dose of GS-9716 to the earlier of the first documentation of definitive progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Time to Response (TTR)</measure>
    <time_frame>First dose date to the first documentation of CR or PR (up to 105 weeks)</time_frame>
    <description>TTR is defined as the time from first dose of GS-9716 to the first documentation of CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Duration of Response (DOR)</measure>
    <time_frame>From first documentation of CR or PR to PD or death, whichever occurs first (up to 37 months)</time_frame>
    <description>DOR is defined as the time from the first documentation of CR or PR to the earlier of the first documentation of definitive disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Overall Survival (OS)</measure>
    <time_frame>First dose date to death (up to 39 months)</time_frame>
    <description>OS is defined as the time from date of first dose of GS-9716 to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>Part A: GS-9716 Dose-Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalating doses of GS-9716 to establish MTD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: GS-9716 Dose-Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the MTD or below MTD of GS-9716.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Cohort B1): GS-9716 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and docetaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Cohort B2): GS-9716 + Sacituzumab Govitecan-hziy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and sacituzumab govitecan-hziy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Cohort B3): GS-9716 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic TNBC will receive combination of GS-9716 and docetaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Cohort B4): GS-9716 + Sacituzumab Govitecan-hziy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic TNBC will receive combination of GS-9716 and sacituzumab govitecan-hziy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Cohort B5): GS-9716 + Docetaxel + Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic STS with nonspecific histologies will receive combination of GS-9716, docetaxel and gemcitabine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C (Cohort C1): GS-9716 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and docetaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C (Cohort C2): GS-9716 + Sacituzumab Govitecan-hziy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and sacituzumab govitecan-hziy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C (Cohort C3): GS-9716 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic TNBC will receive combination of GS-9716 and docetaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C (Cohort C4): GS-9716 + Sacituzumab Govitecan-hziy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic TNBC will receive combination of GS-9716 and sacituzumab govitecan-hziy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C (Cohort C5): GS-9716 + Docetaxel + Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic STS with nonspecific histologies will receive combination of GS-9716, docetaxel and gemcitabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9716</intervention_name>
    <description>Tablet(s) administered orally</description>
    <arm_group_label>Part A: GS-9716 Dose-Escalation</arm_group_label>
    <arm_group_label>Part A: GS-9716 Dose-Expansion</arm_group_label>
    <arm_group_label>Part B (Cohort B1): GS-9716 + Docetaxel</arm_group_label>
    <arm_group_label>Part B (Cohort B2): GS-9716 + Sacituzumab Govitecan-hziy</arm_group_label>
    <arm_group_label>Part B (Cohort B3): GS-9716 + Docetaxel</arm_group_label>
    <arm_group_label>Part B (Cohort B4): GS-9716 + Sacituzumab Govitecan-hziy</arm_group_label>
    <arm_group_label>Part B (Cohort B5): GS-9716 + Docetaxel + Gemcitabine</arm_group_label>
    <arm_group_label>Part C (Cohort C1): GS-9716 + Docetaxel</arm_group_label>
    <arm_group_label>Part C (Cohort C2): GS-9716 + Sacituzumab Govitecan-hziy</arm_group_label>
    <arm_group_label>Part C (Cohort C3): GS-9716 + Docetaxel</arm_group_label>
    <arm_group_label>Part C (Cohort C4): GS-9716 + Sacituzumab Govitecan-hziy</arm_group_label>
    <arm_group_label>Part C (Cohort C5): GS-9716 + Docetaxel + Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Part B (Cohort B1): GS-9716 + Docetaxel</arm_group_label>
    <arm_group_label>Part B (Cohort B3): GS-9716 + Docetaxel</arm_group_label>
    <arm_group_label>Part B (Cohort B5): GS-9716 + Docetaxel + Gemcitabine</arm_group_label>
    <arm_group_label>Part C (Cohort C1): GS-9716 + Docetaxel</arm_group_label>
    <arm_group_label>Part C (Cohort C3): GS-9716 + Docetaxel</arm_group_label>
    <arm_group_label>Part C (Cohort C5): GS-9716 + Docetaxel + Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacituzumab Govitecan-hziy</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Part B (Cohort B2): GS-9716 + Sacituzumab Govitecan-hziy</arm_group_label>
    <arm_group_label>Part B (Cohort B4): GS-9716 + Sacituzumab Govitecan-hziy</arm_group_label>
    <arm_group_label>Part C (Cohort C2): GS-9716 + Sacituzumab Govitecan-hziy</arm_group_label>
    <arm_group_label>Part C (Cohort C4): GS-9716 + Sacituzumab Govitecan-hziy</arm_group_label>
    <other_name>IMMU-132</other_name>
    <other_name>GS-0132</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Part B (Cohort B5): GS-9716 + Docetaxel + Gemcitabine</arm_group_label>
    <arm_group_label>Part C (Cohort C5): GS-9716 + Docetaxel + Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        Part A: GS-9716 Monotherapy&#xD;
&#xD;
          -  Histologically or cytologically confirmed epithelial cancer, stage IV (metastatic)&#xD;
             disease or locally advanced and unresectable (mixed histologies not permitted):&#xD;
&#xD;
               -  Breast cancer&#xD;
&#xD;
               -  Castrate-resistant prostate cancer not on hormonal androgen deprivation therapy&#xD;
&#xD;
               -  Cervical cancer&#xD;
&#xD;
               -  Colorectal cancer&#xD;
&#xD;
               -  Endometrial cancer&#xD;
&#xD;
               -  Epithelial ovarian cancer&#xD;
&#xD;
               -  Esophageal cancer&#xD;
&#xD;
               -  Follicular thyroid cancer&#xD;
&#xD;
               -  Gastric or gastroesophageal junction adenocarcinoma&#xD;
&#xD;
               -  Head and neck cancers- squamous cell carcinoma&#xD;
&#xD;
               -  Hepatocellular carcinoma&#xD;
&#xD;
               -  NSCLC&#xD;
&#xD;
               -  Renal cell cancer (clear cell)&#xD;
&#xD;
               -  Small-cell lung cancer&#xD;
&#xD;
               -  Urothelial cancer&#xD;
&#xD;
          -  Progressed after at least 1 prior standard therapeutic regimen, or for whom no&#xD;
             standard therapy is available, standard therapy has failed, or for whom standard of&#xD;
             care therapy is contraindicated&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per&#xD;
             Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as described in&#xD;
             protocol&#xD;
&#xD;
          -  Adequate hematology, renal and hepatic function as described in the protocol&#xD;
&#xD;
          -  All toxicity at screening ≤ Grade 1, including peripheral neuropathy and excluding&#xD;
             alopecia of any grade, well-controlled endocrine toxicities from prior immune&#xD;
             checkpoint inhibitor therapy ≤ Grade 2, and chronic electrolyte abnormalities&#xD;
             requiring supplementation ≤ Grade 2&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥ 50% acquisition scan (MUGA) may be&#xD;
             acceptable per discussion with the medical monitor&#xD;
&#xD;
          -  Tissue criteria: Individuals must have available, sufficient, and adequate&#xD;
             formalin-fixed tumor tissue sample or must agree to have a biopsy taken prior to&#xD;
             entering the study to provide adequate tissue. Core needle or excisional biopsy or&#xD;
             resected tissue is required.&#xD;
&#xD;
        Part B and Part C: GS-9716 in Combination with Anticancer Therapies (All Cohorts)&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Adequate hematology, renal and hepatic function as described in the protocol&#xD;
&#xD;
          -  Otherwise, all toxicity at screening entry ≤ Grade 1, including peripheral neuropathy&#xD;
             and excluding alopecia of any grade, well-controlled endocrine toxicities from prior&#xD;
             immune checkpoint inhibitor therapy ≤ Grade 2, and chronic electrolyte abnormalities&#xD;
             requiring supplementation ≤ Grade 2&#xD;
&#xD;
          -  LVEF ≥ 50%, as well as no clinically significant pericardial effusion&#xD;
&#xD;
          -  Tissue criteria:&#xD;
&#xD;
               -  TNBC cohorts B3, C3, B4, C4: Individuals must have a tumor lesion that a&#xD;
                  mandatory pretreatment biopsy can be obtained from. Core needle, or excisional&#xD;
                  biopsy, or resected tissue is required. Fine needle aspirates and bone biopsies&#xD;
                  are not acceptable&#xD;
&#xD;
               -  Cohorts B1, C1, B2, C2, B5, C5: Individuals must have available, sufficient, and&#xD;
                  adequate formalin-fixed tumor tissue sample or must agree to have a biopsy taken&#xD;
                  prior to entering the study to provide adequate tissue. Core needle or excisional&#xD;
                  biopsy or resected tissue is required.&#xD;
&#xD;
        Cohorts B1, B2, C1, and C2:&#xD;
&#xD;
          -  Histologically or cytologically confirmed unresectable metastatic or locally advanced,&#xD;
             non-squamous NSCLC following treatment for metastatic disease including an immune&#xD;
             checkpoint inhibitor and a single line of platinum-containing chemotherapy&#xD;
&#xD;
          -  Individuals with bone metastases currently receiving bisphosphonates for palliation&#xD;
             will be eligible providing informed consent can be given and that other qualifying&#xD;
             sites of measurable disease are present.&#xD;
&#xD;
        Cohorts B3, B4, C3, and C4:&#xD;
&#xD;
          -  Histologically or cytologically confirmed TNBC based on the most recent analyzed&#xD;
             biopsy or other pathology specimen. Triple-negative status for TNBC will be defined by&#xD;
             American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP)&#xD;
             guidelines (US sites) or their equivalent (ex-US sites)&#xD;
&#xD;
          -  Unresectable locally advanced or metastatic disease following only 1 prior standard&#xD;
             therapeutic regimen for TNBC. Individuals who have received 2 or more prior systemic&#xD;
             therapies are not eligible&#xD;
&#xD;
          -  Individuals with bone metastases currently receiving bisphosphonates for palliation&#xD;
&#xD;
          -  Individuals with stable, treated brain metastases will be eligible.&#xD;
&#xD;
        Cohorts B5 and C5:&#xD;
&#xD;
          -  Histologically proven soft tissue sarcoma (except the following histologies:&#xD;
             gastrointestinal stromal tumors [GIST], Kaposi's sarcoma, mesotheliomas) which has&#xD;
             been previously untreated for metastatic disease.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with any myeloid cell leukemia 1 (MCL1) inhibitor&#xD;
&#xD;
          -  Treatment with any high dose systemic corticosteroids within 2 weeks of the first dose&#xD;
             of GS-9716. However, low dose corticosteroids ≤ 10 mg prednisone or equivalent daily&#xD;
             is permitted&#xD;
&#xD;
          -  Prior radiotherapy (or other nonsystemic therapy) within 2 weeks prior to dosing with&#xD;
             GS-9716&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Individuals with brain metastases may be enrolled only if treated, nonprogressive, and&#xD;
             asymptomatic as well as off high dose steroids (&gt; 10 mg prednisone or equivalent) for&#xD;
             at least 4 weeks prior to dosing with GS-9716&#xD;
&#xD;
          -  History of leptomeningeal disease&#xD;
&#xD;
          -  Individuals with active ≥ Grade 2 nausea or vomiting, and/or signs of intestinal&#xD;
             obstruction&#xD;
&#xD;
          -  Known active or chronic hepatitis B or C infection or HIV infection or HIV positive&#xD;
&#xD;
          -  Known history of unstable angina, myocardial infarction (MI), cardiac angioplasty or&#xD;
             stenting, or clinically significant cardiac disease would include QTc interval &gt; 450&#xD;
             ms for males and &gt; 470 ms for females&#xD;
&#xD;
          -  Known history of clinically significant active chronic obstructive pulmonary disease&#xD;
             (COPD), or other moderate to severe chronic respiratory illness present within 6&#xD;
             months prior to dosing with GS-9716&#xD;
&#xD;
          -  Known history of clinically significant pulmonary interstitial lung disease, active&#xD;
             interstitial lung disease, idiopathic pulmonary fibrosis, organizing pneumonia (e.g.,&#xD;
             bronchiolitis obliterans), drug induced pneumonitis, or idiopathic pneumonitis, or&#xD;
             evidence of active pneumonitis on screening chest CT scan&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures (more frequently than once monthly)&#xD;
&#xD;
          -  Prior history of clinically significant bleeding, intestinal obstruction, or&#xD;
             gastrointestinal (GI) perforation within 6 months of initiation of study treatment&#xD;
&#xD;
          -  Infection requiring intravenous anti-infective use within 2 weeks prior to dosing with&#xD;
             GS-9716&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency&#xD;
&#xD;
          -  History of uncured coexisting cancer, not including uncured basal cell carcinoma,&#xD;
             cervical cancer in situ, or superficial bladder cancer.&#xD;
&#xD;
        Cohorts B1, B3, B5, C1, C3, and C5:&#xD;
&#xD;
          -  Bilirubin &gt; upper limit of normal (ULN).&#xD;
&#xD;
        Cohorts B1, B2, C1, and C2:&#xD;
&#xD;
          -  More than 1 prior chemotherapy regimen for metastatic non-squamous NSCLC; however,&#xD;
             this would not exclude those who received frontline immune checkpoint inhibitor as&#xD;
             monotherapy followed by a platinum-containing chemotherapeutic regimen in the second&#xD;
             line&#xD;
&#xD;
          -  Non-squamous NSCLC with targetable mutations (e.g., anaplastic lymphoma kinase [ALK],&#xD;
             epidermal growth factor receptor [EGFR], proto-oncogene tyrosine-protein kinase ROS&#xD;
             [ROS1], v-RAF murine sarcoma viral oncogene homolog B [BRAF]) for which approved&#xD;
             therapies are available&#xD;
&#xD;
          -  Cohorts B2 and C2 only: Prior therapy with sacituzumab govitecan-hziy or a&#xD;
             topoisomerase 1 inhibitor or agents targeting Trop-2.&#xD;
&#xD;
        Cohorts B3, B4, C3, and C4:&#xD;
&#xD;
          -  More than 1 prior chemotherapy regimen for metastatic TNBC&#xD;
&#xD;
          -  Cohorts B4 and C4 only: Prior treatment with sacituzumab govitecan-hziy or a&#xD;
             topoisomerase 1 inhibitor or agents targeting Trop-2.&#xD;
&#xD;
        Cohorts B5 and C5:&#xD;
&#xD;
          -  Any previous treatment for metastatic disease&#xD;
&#xD;
          -  Soft tissue sarcomas with the following histologies: GIST, Kaposi's sarcoma, or&#xD;
             mesotheliomas.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Mountain Region</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

